<td class= Dadun
   (New user)
Help  | Contact  |  Castellano English  

Dadun > Depósito Académico > CIMA (Centro de Investigación Médica Aplicada) > Área de Ciencias Cardiovasculares > Aterosclerosis e inflamación > DA - CIMA - Cardiovasculares - Aterosclerosis e inflamación - Artículos de revista >

Tratamiento del síndrome antifosfolípido
Authors: Paramo, J.A. (José Antonio)
Garcia, R. (R.)
Rodriguez, P. (P.)
Panizo, E. (E.)
Lecumberri, E. (E.)
Keywords: Antiphospholipid syndrome
Fetal death
Lupus anticoagulant
Issue Date: 2007
Publisher: Ediciones Universidad de Navarra
Publisher version:
ISSN: 0556-6177
Citation: Paramo JA, Garcia R, Rodriguez P, Panizo E, Lecumberri R. Tratamiento del síndrome antifosfolípido. Rev Med Univ Navarra 2007 Oct-Dec;51(4):38-41.
The antiphospholipid syndrome (APS) is a disorder of recurrent thrombosis and/or pregnancy loss associated with the presence of antiphospholipid antibodies and persistently positive lupus anticoagulant, anticardiolipin or anti beta2-glycoprotein1. Oral anticoagulants are the best available and most effective treatment for the secondary prevention of recurrent venous or arterial thrombosis. Patients with APS are treated with long-term therapy to prolong the INR to 2.0-3.0. Low-molecular-weight heparin in combination with low-aspirin dose is a reasonable strategy to avoid pregnancy loss in women with this syndrome.
Permanent link:
Appears in Collections:DA - Medicina - Hematología - Artículos de revista
DA - CUN - Hematología y Hemoterapia - Artículos de revista
DA - CIMA - Cardiovasculares - Aterosclerosis e inflamación - Artículos de revista

Files in This Item:
File:  RevMedUnivNavarra2007_5143841.pdf
Size:  28,42 kB
Format:  Adobe PDF
 View / Open 

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.